At the news
? NEUTRALIMPACT 5/10 8-K filed Apr 9, 2026 at 07:13 ET
Invivyd announced progress in its VYD2311 program for COVID-19 prevention and the discovery of a new measles monoclonal antibody candidate, VMS063. The company provided updates on clinical trial advancements and pipeline progress.
- Invivyd announced progress in its REVOLUTION program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention
- The DECLARATION Phase 3 study for VYD2311 has been upsized by approximately 500 additional subjects
- Top-line results for the DECLARATION study are now expected in Q3 2026, shifting from mid-year guidance
- The company has aligned with the FDA on an initial pediatric study plan for VYD2311
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access